Galectin Therapeutics (GALT) Announces OncoImmunology Publishes Pre-clinical Research Showing Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
Go back to Galectin Therapeutics (GALT) Announces OncoImmunology Publishes Pre-clinical Research Showing Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy| GALECTIN (NASDAQ: GALT) | Delayed: 3.41 +0.03 (0.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.38 | 52 Week High | $3.05 | |||
| Open | $3.37 | 52 Week Low | $0.49 | |||
| Day High | $3.45 | P/E | N/A | |||
| Day Low | $3.25 | EPS | $-1.32 | |||
| Volume | 83,068 | |||||
